CNST News and Press, Constellation Pharmaceuticals Inc. From 09/08/20

Oppenheimer analyst Silvan Tuerkcan has downgraded Constellation Pharmaceuticals ( CNST -4.0% ) to Perform from Outperform, and lowered price target to $20 from $47 driven by new 25% Probability of Success versus prior 60% for its lead asset CPI-0610, in myelofibrosis, a rare bone marrow c...

Constellation Pharmaceuticals, Inc. (CNST) Q2 2020 Results Conference Call August 02, 2020 08:00 AM ET Company Participants Kia Khaleghpour - VP, IR and Communications Jigar Raythatha - CEO Dr. Jeff Humphrey - Chief Medical Officer Dr. Patrick Trojer - Chief Scientific Officer ...

Image source: The Motley Fool. Constellation Pharmaceuticals   (NASDAQ: CNST) Q2 2020 Earnings Call Aug 7, 2020 , 10:00 p.m. ET Operator Continue reading

Constellation Pharmaceuticals (NASDAQ: CNST ) : Q2 GAAP EPS of -$0.70 misses by $0.07 . More news on: Constellation Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20 Constellation plans to explore additional indications for CPI-0610 CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharm...

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss it...

Investment Thesis Constellation Pharmaceuticals share price performance since IPO. Source: TradingView . Since launching a scaled-down IPO in July 2019 at $15 per share that raised ~$60m - as opposed to the $80m it had originally sought - Constellation Pharmaceuticals ( CNST ) has deliv...

Takeda Reports Positive Data for Late Stage Multiple Myeloma Trial Takeda Pharmaceutical Company Limited (TAK) announced data from its Phase 3 clinical trial of single-agent oral NINLARO as well as from the US MM-6 study. NINLARO, in combination with lenalidomide and dexamethasone, is curr...

Constellation Pharmaceuticals (NASDAQ: CNST ) has priced its public offering of 5.5M common shares at $35.00/share, for total gross proceeds of $192.5M. More news on: Constellation Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. These small-cap biotechnology stocks when held in the long term can...